IQVIA (IQV) Q3 2026 Earnings Call Transcript

IQVIA reported Q3 2026 revenue of $4.43 billion, up 8% year over year, and adjusted diluted EPS of $3.34, up 11.3%; revenue, adjusted EBITDA and EPS exceeded the high end of management’s guidance. R&D net new bookings rose 15% to $3.2 billion, with a 1.2 book-to-bill ratio, while the company raised full-year revenue guidance to $17.35–$17.50 billion and adjusted EPS guidance to $12.90–$13.00. Management cited improving demand and AI adoption, including 415 agents deployed, while noting a roughly 70-basis-point margin headwind from pass-through revenues; IQVIA also removed $2.1 billion of inactive trials from contracted backlog, which stood at $32.6 billion after the adjustment.

Analysis

The key read-through is a turn in outsourced clinical demand, not a near-term AI revenue step-change. Rising bookings and improving win rates can support revenue for several quarters given CRO project lead times; the five-quarter bookings trend is more informative than one quarter’s book-to-bill. If funding and trial starts persist, IQVIA’s scale and integrated data/services may shift share toward it from smaller CROs, though that remains management’s competitive claim rather than proof of durable pricing power.

Near term, reported margin optics may remain noisy: full-service work brings pass-through costs, while management’s operational improvement is not fully visible in reported margins. Guidance also includes a meaningful acquisition contribution, so organic execution—not headline revenue—is the cleaner test. The 3.45x net leverage makes sustained free cash flow important and may constrain capital returns or further deal capacity.

Over 1–3 months, the December 1 Investor Day is the catalyst for 2027 growth and margin expectations. Over 6–18 months, monitor whether funding converts into signed awards and revenue, and whether AI creates billable services or simply improves win rates/productivity. Contrarian risk: strong bookings and AI positioning may already be reflected in IQV; agent deployment counts do not establish incremental revenue or returns. Falsifiers include weakening LTM bookings or 12-month backlog conversion, organic growth slowing, EBITDA-dollar guidance cuts, or leverage rising.

Key Decisions for Investors

• Consider a staged long IQV on post-earnings weakness rather than chasing the beat; require valuation and price-action review before sizing. Thesis: improving bookings support forward growth, but the near-term catalyst is 2027 guidance, not agent counts.
• Prefer IQV to smaller CRO peers only as a relative-value watch: the share-gain thesis is plausible, but verify competitor booking trends and IQV pricing/mix before putting on a pair trade.
• At the December 1 Investor Day, test whether 2027 targets show organic growth and EBITDA-dollar progress independent of acquisitions and pass-through mix. Reassess if organic growth or LTM bookings roll over.
• Track quarterly free cash flow, net leverage, and backlog conversion; weaker cash generation or leverage moving higher would undermine the equity upside even if reported revenue remains strong.